Cross-institution positioning
Aug 7, 2026Mixed positioning. 1 accumulating, 2 reducing across 3 comparable institutions.
Source: Schedule 13 researchVir Biotechnology, Inc.
Latest stored close $11.52 as of Oct 7, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Mixed positioning. 1 accumulating, 2 reducing across 3 comparable institutions.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsRecent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/54 non-amendment material events in the last 90 days; Latest classified evidence: Other event. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue +19,582.5% YoY; Net income +172.2% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 79% through its reported 52-week range; +118.0% over one year.
Source: Stored historical price seriesFiled Aug 7, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | MORE ROBERT J | JOther transaction | Common Stock | 8.0K | $0.00 | Indirect | Aug 12, 2026 |
| Aug 11, 2026 | MORE ROBERT J | JOther transaction | Common Stock | 8.0K | $0.00 | Direct | Aug 12, 2026 |
| Jun 9, 2026 | Coughlin Timothy | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | Jun 10, 2026 |
| Jun 9, 2026 | Coughlin Timothy | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | Jun 10, 2026 |
| Jun 9, 2026 | Coughlin Timothy | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | Jun 10, 2026 |
| Jun 9, 2026 | Coughlin Timothy | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | Jun 10, 2026 |
| Jun 1, 2026 | Napolitano Janet | SOpen-market or private sale | Common Stock | 3.2K | $9.45 | Direct | Jun 2, 2026 |
| Jun 1, 2026 | Sabatini Brent | SOpen-market or private sale | Common Stock | 379 | $9.45 | Direct | Jun 2, 2026 |
| May 27, 2026 | Sigal Charles Elliott | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | Sigal Charles Elliott | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | Napolitano Janet | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | Napolitano Janet | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | MORE ROBERT J | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | MORE ROBERT J | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | Hatfield Jeffrey S. | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | Hatfield Jeffrey S. | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | Farid Ramy | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | Farid Ramy | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | BISCHOFBERGER NORBERT W | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 16.0K | $0.00 | Direct | May 28, 2026 |
| May 27, 2026 | BISCHOFBERGER NORBERT W | AGrant, award, or other acquisition | Common Stock | 8.0K | $0.00 | Direct | May 28, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Oct 8, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Oct 1, 2026 | 8-K | 5.02, 7.01, 9.01 | Director or executive change; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 5, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 24, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Jun 10, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| May 28, 2026 | 8-K | 5.02, 5.07 | Director or executive change; Shareholder vote results | — | Filing |
| May 6, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Apr 10, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Mar 4, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Mar 2, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Feb 26, 2026 | 8-K | 1.01, 9.01 | Material definitive agreement; Financial statements / exhibits | — | Filing |
| Feb 26, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $238.9M | +19,582.5% |
| Ended Mar 31, 2026 | $-29.0K | -101.0% |
| Ended Sep 30, 2025 | $240.0K | -89.9% |
| Ended Jun 30, 2025 | $1.2M | -60.5% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $68.6M | -7.6% |
| Ended Dec 31, 2024 | $74.2M | -13.9% |
| Ended Dec 31, 2023 | $86.2M | -94.7% |
| Ended Dec 31, 2022 | $1.6B | +47.5% |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| State Street CIK0000093751 | Jun 30, 2026 observed Aug 7, 2026 filed · 38d Initial Schedule 13G | Initial Schedule 13G | 10.0M +4.3M | 5.90% +1.80 pts | $10.19 | $8.97 | $11.52 |
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment | Reported reduction | 11 -12.3M | 12.00% +2.86 pts | $9.26 | $8.40 | $11.52 |
| BlackRock CIK0002012383 | Mar 31, 2025 observed Apr 28, 2025 filed · 28d Schedule 13G amendment | Earliest Schedule 13G amendment found | 14.8M | 10.80% | $6.48 | $6.10 | $11.52 |
Compare VIR with other securities showing similar institutional activity or recent accumulation across several tracked institutions.